Welcome to our dedicated page for Apogee Therapeutics news (Ticker: APGE), a resource for investors and traders seeking the latest updates and insights on Apogee Therapeutics stock.
Apogee Therapeutics, Inc. develops novel biologic antibody programs for inflammatory and immunology diseases, with disclosed focus areas including atopic dermatitis, asthma, eosinophilic esophagitis and chronic obstructive pulmonary disease. Its programs target established mechanisms of action and use antibody engineering intended to optimize half-life and dosing properties.
Recurring APGE news includes clinical data and pipeline updates for zumilokibart (APG777), APG279, which combines zumilokibart with APG990, and APG333. Company updates also cover operating and financial results, public equity offerings, management conference participation, shareholder-voting matters, governance changes and financing activity to support preclinical studies, clinical trials, manufacturing, commercial readiness and general corporate purposes.
AbbVie (ABBV) completed its acquisition of Apogee Therapeutics (APGE), paying $135.11 in cash per share, implying equity value of approximately $10.9 billion as of September 3, 2026.
The acquisition adds Apogee's immunology pipeline, led by zumilokibart, a late-stage, half-life extended IL-13 monoclonal antibody in development for atopic dermatitis and other inflammatory diseases. In a Phase 2 trial in atopic dermatitis, roughly two-thirds of patients on zumilokibart achieved significant skin clearance at 16 weeks, with improved itch and disease control, and data support quarterly or twice-yearly dosing with a favorable safety profile.
The deal also brings APG273, a long-acting combination of zumilokibart and APG333 targeting IL-13 and TSLP for asthma. AbbVie expects EPS dilution of $0.14 in 2026 and about $0.46 in 2027, but reaffirmed 2026 full-year adjusted diluted EPS guidance of $13.87–$14.07 and third-quarter guidance of $3.84–$3.88.
Apogee Therapeutics (Nasdaq: APGE) reported Q2 2026 results alongside major strategic and pipeline updates. AbbVie agreed to acquire Apogee for $135.11 per share in cash, valuing the company at about $10.9 billion, with closing expected in Q3 2026, subject to shareholder and regulatory approvals.
Apogee also entered a up to $1.3 billion non-dilutive financing collaboration with Blackstone Life Sciences to support Phase 3 and potential commercialization of zumilokibart. In the APEX Phase 2 Part B trial in atopic dermatitis, mid-dose zumilokibart achieved 65.9% EASI-75 (41.9% placebo-adjusted) and met all primary and secondary endpoints with statistical significance.
Cash, cash equivalents and marketable securities reached $1.3 billion at June 30, 2026. Q2 R&D expenses were $67.3 million, G&A expenses $24.3 million, and net loss $85.9 million, all higher year over year, driven by pipeline advancement and organizational growth.
AbbVie (NYSE: ABBV) agreed to acquire Apogee Therapeutics for $135.11 per share in cash, valuing Apogee at about $10.9 billion. The deal adds late-stage immunology assets, including lead antibody zumilokibart (APG777) for atopic dermatitis and APG273 for asthma, and is expected to close in Q3 2026 and be accretive to adjusted diluted EPS beginning in 2032.
Apogee Therapeutics (Nasdaq: APGE) announced management participation in two June 2026 investor conferences.
The company will join the Jefferies Global Healthcare Conference on June 3, 2026 at 11:40 a.m. ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026 at 9:20 a.m. ET. Live and archived webcasts will be accessible on Apogee's investor website.
Apogee Therapeutics (Nasdaq: APGE) entered a strategic financing collaboration with Blackstone Life Sciences for up to $1.3 billion in flexible, non-dilutive capital to advance Phase 3 development and potential commercialization of zumilokibart.
The deal includes up to $800 million in synthetic royalty funding and access to up to $500 million in senior corporate debt. Combined with Apogee’s $1.3 billion in cash, the company believes this supports a self-sustainable financial profile through commercialization without future equity financing.
Apogee Therapeutics (Nasdaq: APGE) reported positive 16-week Part B results from its Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis.
The trial met all primary and secondary endpoints; 65.9% of mid-dose patients achieved EASI-75 vs 23.4% placebo. Mid-dose will advance to planned Phase 3 in 2H 2026. Safety was generally consistent with class. A new financing collaboration with Blackstone Life Sciences is expected to fund development through potential commercialization in AD, asthma and EoE.
Apogee Therapeutics (Nasdaq: APGE) will report Part B 16-week data from the Phase 2 APEX trial of zumilokibart in moderate-to-severe atopic dermatitis on May 27, 2026. The company will host a conference call and live webcast at 8:00 a.m. ET, with a replay available afterward via its investor website.
Apogee Therapeutics (Nasdaq: APGE) reported Q1 2026 results and major pipeline progress. Cash, cash equivalents and securities rose to $1.3 billion, aided by a $403 million upsized equity offering, extending runway into 2029.
Phase 2 APEX 52-week data for zumilokibart in atopic dermatitis showed durable maintenance and improved efficacy with every 3- and 6-month dosing, supporting planned Phase 3 initiation in 2H 2026 and a future BLA filing in AD.
Apogee Therapeutics (Nasdaq: APGE) closed an underwritten public offering of 5,750,000 common shares at $70.00 per share, including full exercise of the underwriters’ option for 750,000 additional shares, generating approximately $403 million in gross proceeds before fees.
The offering used an effective shelf registration filed August 12, 2024, and was led by Jefferies, TD Cowen, Stifel and Guggenheim.
Apogee Therapeutics (Nasdaq: APGE) priced an underwritten public offering of 5,000,000 common shares at $70.00 per share, for aggregate gross proceeds of approximately $350 million.
The offering is expected to close on March 26, 2026, subject to customary closing conditions, and underwriters have a 30-day option to purchase up to an additional 750,000 shares.